UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): April 26, 2018

PFIZER INC.

(Exact name of registrant as specified in its charter)

Delaware

1-3619

13-5315170

(State or other jurisdiction of incorporation)

(Commission File Number)

(I.R.S. Employer Identification No.)

235 East 42nd Street

New York, New York

(Address of principal executive offices)

10017

(Zip Code)

Registrant's telephone number, including area code:

(212) 733-2323

Not Applicable

(Former Name or Former Address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the obligation of the registrant under any of the following provisions:

[ ] Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 ( 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 ( 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 5.07

Submission of Matters to a Vote of Security Holders

(a) The Pfizer Inc. (the "Company") Annual Meeting of Shareholders was held on April 26, 2018.

(b) Shareholders voted on the matters set forth below.

1. The nominees for election to the Company s Board of Directors were elected to hold office until the Company s next Annual Meeting of Shareholders, based upon the following votes:

Nominee

Votes For

Votes Against

Abstentions

Broker non-vote

Dennis A. Ausiello

4,108,728,641

79,882,319

11,520,427

923,139,453

Ronald E. Blaylock

4,102,046,338

81,670,030

16,414,332

923,139,453

Albert Bourla

4,066,124,646

122,714,120

11,292,006

923,139,453

W. Don Cornwell

3,984,735,073

201,815,697

13,572,919

923,139,453

Joseph J. Echevarria

4,009,427,816

128,789,526

61,914,045

923,139,453

Helen H. Hobbs

4,158,460,045

31,222,644

10,447,449

923,139,453

James M. Kilts

4,025,819,403

162,514,018

11,797,816

923,139,453

Dan R. Littman

4,155,203,205

33,499,038

11,428,230

923,139,453

Shantanu Narayen

4,121,708,670

66,768,599

11,643,247

923,139,453

Suzanne Nora Johnson

4,065,134,950

124,218,718

10,766,918

923,139,453

Ian C. Read

3,970,452,334

199,049,638

30,624,121

923,139,453

James C. Smith

4,133,648,657

52,974,916

13,507,065

923,139,453

2. The proposal to ratify the selection of KPMG LLP as the Company s independent registered public accounting firm for the 2018 fiscal year was approved based upon the following votes:

Votes for approval

4,938,011,334

Votes against

170,765,860

Abstentions

14,484,272

Broker non-votes

n/a

3. The proposal to approve, on an advisory basis, the compensation of the Company's Named Executive Officers was approved based upon the following votes:

Votes for approval

3,865,836,269

Votes against

307,749,940

Abstentions

26,544,915

Broker non-votes

923,139,453

4. The proposal to approve the Pfizer Inc. French Sub-Plan under the 2014 Stock Plan was approved based upon the following votes:

Votes for approval

4,009,297,297

Votes against

156,668,597

Abstentions

34,165,493

Broker non-votes

923,139,453

5. The shareholder proposal regarding right to act by written consent was not approved based upon the following votes:

Votes for approval

1,509,956,494

Votes against

2,656,246,000

Abstentions

33,927,896

Broker non-votes

923,139,453

6. The shareholder proposal regarding independent chair policy was not approved based upon the following votes:

Votes for approval

1,067,768,186

Votes against

3,103,947,589

Abstentions

28,415,466

Broker non-votes

923,139,453

7. The shareholder proposal regarding report on lobbying activities was not approved based upon the following votes:

Votes for approval

1,363,371,782

Votes against

2,710,672,755

Abstentions

126,085,108

Broker non-votes

923,139,453

(c) Not applicable

(d) Not applicable

SIGNATURE

Under the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the authorized undersigned.

PFIZER INC.

Dated: May 1, 2018

By: /s/ Margaret M. Madden

Margaret M. Madden

Title: Senior Vice President & Corporate Secretary

Chief Governance Counsel